Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The tamoxifen dilemma.

I N White1

  • 1MRC Toxicology Unit, Hodgkin Building, Lancaster Road, Leicester LE1 9HN, UK.

Carcinogenesis
|June 29, 1999
PubMed
Summary

Tamoxifen, used for breast cancer treatment, may increase endometrial cancer risk. While liver cancer risk in humans is low due to minimal DNA damage, the cause of endometrial cancer remains unclear.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suicidal destruction of cytochrome p-450 by ethynyl substituted compounds.

Pharmaceutical research·2013
Same author

Preparation of rat lung cells for flow cytometry.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Preparation of rat lung cells for flow cytometry.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

The role of CYP forms in the metabolism and metabolic activation of HCFCs and other halocarbons.

Toxicology letters·2001
Same author

Neoantigen formation and clastogenic action of HCFC-123 and perchloroethylene in human MCL-5 cells.

Toxicology letters·2001
Same author

Bioactivation and toxicity in vitro of HCFC-123 and HCFC-141b: role of cytochrome P450.

Toxicology letters·2001

Area of Science:

  • Pharmacology
  • Oncology
  • Toxicology

Background:

  • Tamoxifen is a widely used anti-oestrogen for breast cancer adjuvant therapy.
  • Tamoxifen has shown potential as a breast cancer chemopreventive agent.
  • Epidemiological studies indicate tamoxifen use is associated with an increased incidence of endometrial cancers.

Purpose of the Study:

  • To investigate the genotoxic and carcinogenic potential of tamoxifen, particularly concerning liver and endometrial tissues.
  • To compare tamoxifen's metabolic activation and DNA binding in rats and humans.
  • To elucidate the mechanism behind tamoxifen-induced endometrial cancer in treated women.

Main Methods:

  • Review of epidemiological studies on tamoxifen users.
  • Analysis of rat studies on tamoxifen's genotoxicity and carcinogenicity.
  • Investigation of DNA adduct formation in human uterine endometrium using techniques like 32P-post-labelling and accelerator mass spectrometry.

Main Results:

  • Tamoxifen is a genotoxic liver carcinogen in rats, activated by CYP enzymes to electrophiles that bind DNA.
  • DNA damage in rats is dose- and duration-dependent.
  • Evidence of similar DNA binding in human uterine endometrium is inconclusive and at very low levels; human liver cancer risk is deemed insignificant.

Conclusions:

  • Tamoxifen's use in breast cancer patients is justified despite increased endometrial cancer risk.
  • The mechanism for tamoxifen-induced endometrial cancer in humans is uncertain and unlikely to be a classical genotoxic pathway.
  • Further research is needed to fully understand tamoxifen's effects on endometrial tissue.

Related Experiment Videos